Female, n (%) | 12 (80) | 13 (81) | 12 (80) | 9 (60) | 13 (81) | 13 (76) | 12 (71) | 13 (81) |
Age, yrs, mean ± SD | 54.2 ± 14.3 | 52.4 ± 12.5 | 51.5 ± 12.8 | 55.2 ± 12.4 | 56.6 ± 13.7 | 52.4 ± 14.3 | 51.6 ± 13.7 | 52.7 ± 13.7 |
Caucasian, n (%) | 14 (93) | 15 (94) | 14 (93) | 12 (80) | 13 (81) | 14 (82) | 15 (88) | 13 (81) |
Type of arthritis, n (%) |
Rheumatoid arthritis | 13 (87) | 13 (81) | 9 (60) | 11 (73) | 12 (75) | 15 (88) | 13 (76) | 15 (94) |
Psoriatic spondylitis | 2 (13) | 2 (13) | 4 (27) | 4 (27) | 3 (19) | 1 (6) | 4 (24) | 1 (6) |
Ankylosing spondylitis | 0 | 1 (6) | 2 (13) | 0 | 1 (6) | 1 (6) | 0 | 0 |
Target joint, n (%) |
Knee | 7 (47) | 9 (56) | 8 (53) | 6 (40) | 6 (38) | 4 (24) | 7 (41) | 3 (19) |
Ankle | 2 (13) | 3 (19) | 4 (27) | 1 (7) | 3 (19) | 2 (12) | 4 (24) | 5 (31) |
Wrist | 5 (33) | 2 (13) | 2 (13) | 2 (13) | 5 (31) | 4 (24) | 3 (18) | 6 (38) |
Metacarpophalangeal | 1 (7) | 2 (13) | 1 (7) | 2 (13) | 2 (13) | 4 (24) | 2 (12) | 1 (6) |
Elbow | 0 | 0 | 0 | 4 (27) | 0 | 3 (18) | 1 (6) | 1 (6) |
Currently taking TNF-α antagonist, n (%) | 9 (60) | 8 (50) | 10 (67) | 7 (47) | 8 (50) | 12 (71) | 7 (41) | 10 (63) |
Etanercept/infliximab/adalimumab | 6/1/2 | 4/1/3 | 6/2/2 | 4/1/2 | 5/0/3 | 7/1/4 | 3/2/2 | 4/3/3 |
Currently taking methotrexate, n (%) | 12 (80) | 13 (81) | 8 (53) | 12 (80) | 13 (81) | 10 (59) | 12 (71) | 11 (69) |
Currently taking prednisone, n (%) | 5 (33) | 11 (69) | 5 (33) | 6 (40) | 5 (31) | 4 (24) | 5 (29) | 4 (25) |
Disease status, mean ± SD |
Swollen joints (28 count) | 4.2 ± 4.2 | 9.4 ± 7.5 | 7.4 ± 7.9 | 5.6 ± 7.5 | 7.9 ± 6.4 | 5.7 ± 4.9 | 5.9 ± 7.3 | 5.3 ± 6.1 |
Tender joints (28 count) | 5.8 ± 5.8 | 9.7 ± 6.9 | 5.8 ± 6.3 | 3.8 ± 3.6 | 8.9 ± 8.2 | 7.4 ± 6.8 | 6.6 ± 8.7 | 5.1 ± 6.1 |
Patient global assessment (cm) | 4.3 ± 2.3 | 6.0 ± 1.4 | 4.9 ± 2.0 | 4.8 ± 2.1 | 5.1 ± 2.0 | 4.6 ± 2.5 | 5.9 ± 2.7 | 4.9 ± 2.6 |
Patient assessment of pain (cm) | 3.7 ± 2.3 | 5.5 ± 2.1 | 4.5 ± 2.3 | 4.3 ± 2.2 | 5.1 ± 2.4 | 4.0 ± 2.5 | 5.7 ± 2.8 | 4.7 ± 2.7 |
Health assessment questionnaire | 1.0 ± 0.5 | 1.4 ± 0.7 | 1.3 ± 0.5 | 0.9 ± 0.5 | 1.1 ± 0.7 | 1.2 ± 0.6 | 1.2 ± 0.7 | 1.0 ± 0.7 |
Physician global assessment (cm) | 3.7 ± 1.5 | 4.5 ± 1.7 | 3.8 ± 1.9 | 3.5 ± 1.9 | 4.0 ± 1.9 | 3.6 ± 2.2 | 5.0 ± 1.8 | 3.7 ± 1.7 |
Erythrocyte sedimentation rate, mm/h | 26 ± 18 | 18 ± 14 | 20 ± 11 | 22 ± 13 | 34 ± 36 | 24 ± 21 | 31 ± 29 | 30 ± 29 |
Disease Activity Score | 3.8 ± 1.1 | 4.2 ± 1.4 | 4.0 ± 1.3 | 3.6 ± 0.9 | 4.3 ± 1.6 | 4.0 ± 1.3 | 3.9 ± 1.3 | 3.7 ± 1.3 |